---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042879"
form_type: "8-K/A"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-10-16T23:59:59+00:00"
generated_at: "2026-05-30T13:45:21.235221+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics appoints Paige Mahaney as CSO effective Oct 28; Stewart Fisher retires

## Summary
- Paige Mahaney, Ph.D., formerly SVP at Exelixis, appointed CSO effective October 28, 2024.
- Stewart Fisher, Ph.D., retires as CSO Oct 28, will serve as Senior Scientific Advisor through Dec 2024, then consultant through Dec 2025.
- Mahaney receives $510k base salary, $150k sign-on bonus, up to $75k relocation, and performance bonus up to 40% of base.
- Mahaney granted inducement option for 345,600 shares (25% vests at 1 yr, rest over 3 yrs) and RSUs for 76,800 shares (vest over 4 yrs).
- Fisher's retirement not due to any disagreement; consulting agreement provides continued equity vesting through Dec 2025.

## SEC filing metadata
- accession: 0001628280-24-042879
- form_type: 8-K/A
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/0001628280-24-042879-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/cccc-20241015.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042879
- JSON: https://secwatch.observer/filing/0001628280-24-042879.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042879.txt

## Key facts
- Executive change
  Paige Mahaney was appointed as Chief Scientific Officer at C4 Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/0001628280-24-042879-index.htm
- Executive change
  Stewart Fisher retired as Chief Scientific Officer at C4 Therapeutics, Inc..
  - Action: retired
  - Role: Chief Scientific Officer
  source text: On October 11, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024042879/0001628280-24-042879-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.